Provenance Record

Clear, well-structured clinical report using the house News template (Overview / What We Know / Why It Matters / What We Don't Know). 633 words, within the News 400-1200 range. Appropriate technical depth for a phase III oncology trial readout; the limitations section is honest about the radiotherapy-confounded population and pending longer follow-up.

All 4 source snapshots read from disk and verified (Rule 9 clinical scrutiny applied). source-0 (The ASCO Post, HTTP 200): confirms 5-yr OS 93.4% vs 94.4%, median follow-up 60.1 months, BCSS 97.2% vs 97.9%, Lymph-ICF mean difference 10.75 points, abstract LBA503, Jana de Boniface (lead investigator, Capio St. Goran's Hospital / Karolinska Institutet), and the direct quote verbatim ('...axillary surgery should be seen as a diagnostic instrument, not a therapeutic tool'). source-1 (CancerNetwork, HTTP 200): confirms HR 0.89 (95% CI 0.67-1.17), non-inferiority P<.001, OS 93.4%/94.4%, severe arm dysfunction 12.6% vs 3.6% (statistically significant), regional radiotherapy 87.9% vs 89.7%. source-2 (CancerNetwork, HTTP 200): confirms median age 61, eligibility (1-2 sentinel macrometastases >2 mm), Jane Lowe Meisel (Winship Cancer Institute, Emory) and lymphedema framing, and the mastectomy/larger-tumor de-escalation context. source-3 (OncoDaily, HTTP 200): confirms 2,766 randomized across five countries (Jan 2015-Dec 2021), per-protocol 2,540 (1,205 ALND / 1,335 omission), 196 deaths incl. 75 breast-cancer deaths, non-inferiority margin (HR <1.44, upper one-sided 90% CI).

Every statistic in the headline, summary, and Overview lead traces verbatim to a fetchable allowlisted snapshot. CRITICAL Rule 9/5i checks: NEJM (NEJMoa2313487) and the ASCO/JCO abstract (ascopubs.org LBA503) both 403'd and are NOT cited inline or in article.sources — confirmed zero occurrences. Data-conflict resolution verified: OncoDaily's snapshot reports HR 0.84/0.86, but the article correctly uses HR 0.89 cited to CancerNetwork, matching The ASCO Post and both CancerNetwork pieces; the rejected 0.84 does not appear anywhere in the article. Sound editorial judgment by the contributor. One body-level misattribution (see findings): the mastectomy/T3 broadened-populations claim is cited to the wrong CancerNetwork article; the fact itself is accurate and present in the other cited sources.

High-quality, source-faithful clinical report that survives rigorous Rule 9 verification: no reliance on the 403'd NEJM/ascopubs primaries, every statistic carried verbatim by a fetchable allowlisted outlet, the HR data conflict correctly resolved to 0.89, and the de Boniface quote verbatim with the correct speaker. The sole issue is a single wrong-outlet cite for a verifiable body claim — honestly summarizable in one correction. Verdict: APPROVE_WITH_CORRECTIONS.